Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LIN28B siRNA+BMN673

ABSTRACT: Malignant serous effusion (MSE) is a common and severe complication in advanced malignancies, associated with poor prognosis and high recurrence rates. To date, no standardized treatments are available for MSE management, posing significant clinical challenges. Here, we identify aberrant LIN28B expression and dysregulation of DNA repair pathways in MSE patient samples and preclinical models. We developed a nanoparticle delivery system incorporating LIN28B siRNA (siRNA/DSSP@lip-PEG-FA) to specifically inhibit LIN28B function. Combined with the PARP inhibitor BMN673, this nanoparticle system significantly alleviates MSE accumulation and prolongs survival in preclinical models without systemic cytotoxicity. Mechanistically,bulk RNA sequencing (RNAseq) of A2780 reveals that this combination therapy markedly remodels the immune microenvironment by decreasing M2 macrophages and increasing neutrophil components with altered subtypes. Notably, Arg1-positive neutrophils, which produce pro-inflammatory cytokines to increase vascular permeability, are diminished by the combination treatment. Furthermore, In vitro and in vivo experiments demonstrate that our approach inhibits vascular leakage and strengthens the rigidity of tight junction, suggesting suppression of vascular permeability. Together, our findings establish dual-targeting of PARP and LIN28B as a promising therapeutic strategy for MSE management in advanced cancers, with the potential to improve patient quality of life.

ORGANISM(S): Homo sapiens

PROVIDER: GSE295677 | GEO | 2026/04/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Dual-targeting PARP and LIN28B alleviates the accumulation of malignant serous effusion by decreasing vascular permeability

Project description:Malignant serous effusion (MSE) is a common and severe complication in advanced malignancies, associated with poor prognosis and high recurrence rates. To date, no standardized treatments are available for MSE management, posing significant clinical challenges. Here, we identify aberrant LIN28B expression and dysregulation of DNA repair pathways in MSE patient samples and preclinical models. We developed a nanoparticle delivery system incorporating LIN28B siRNA (siRNA/DSSP@lip-PEG-FA) to specifically inhibit LIN28B function. Combined with the PARP inhibitor BMN673, this nanoparticle system significantly alleviates MSE accumulation and prolongs survival in preclinical models without systemic cytotoxicity. Mechanistically, single-cell RNA sequencing (scRNAseq) reveals that this combination therapy markedly remodels the immune microenvironment by decreasing M2 macrophages and increasing neutrophil components with altered subtypes. Notably, Arg1-positive neutrophils, which produce pro-inflammatory cytokines to increase vascular permeability, are diminished by the combination treatment. Furthermore, In vitro and in vivo experiments demonstrate that our approach inhibits vascular leakage and strengthens the rigidity of tight junction, suggesting suppression of vascular permeability. Together, our findings establish dual-targeting of PARP and LIN28B as a promising therapeutic strategy for MSE management in advanced cancers, with the potential to improve patient quality of life.

2026-04-09 | GSE293216 | GEO

LIN28B siRNA+BMN673

Project description:LIN28B siRNA+BMN673

| PRJNA1255576 | ENA

Dual-targeting PARP and LIN28B alleviates the accumulation of malignant serous effusion by decreasing vascular permeability

Project description:Dual-targeting PARP and LIN28B alleviates the accumulation of malignant serous effusion by decreasing vascular permeability

| PRJNA1243366 | ENA

role of LIN28B protein in medulloblastoma by siRNA-mediated silencing of LIN28B in Daoy cells

Project description:To understand the role of LIN28B protein in medulloblastoma by siRNA-mediated silencing of LIN28B in Daoy cells and analysing the differentially-regulated proteins and pathways.

2025-05-06 | PXD022481 | Pride

CXCL10 promotes vascular permeability upon TNF-induced release from pericytes

Project description:Tumor necrosis factor alpha induces vascular permeability, playing an important role in inflammation. Also, TNF-induced vascular leakage is involved in the increased extravasation of nanoparticle formulated chemotherapeutics improving drug delivery and subsequently tumor response, and we found a positive correlation between the presence of pericytes in the tumor-associated vasculature and TNF-induced leakage. RNA sequencing and pathway analysis of TNF-stimulated versus non-stimulated pericytes and endothelial cells show significant upregulation of several pathways involving interferon regulating pathways with a high expression of CXCL10, also known as Interferon gamma-inducible protein 10 (IP-10) in TNF-stimulated pericytes. In addition, CXCL10 protein production was significantly increased in conditioned medium from TNF-exposed pericytes compared to the other conditions. In our animal studies, we observed that tumor types with high pericyte covered vessels show enhanced permeability when exposed to TNF, which can be blocked with a neutralizing CXCL10 antibody. Vice versa, tumors with vessels low in pericyte number do not respond to TNF, i.e., do not express elevated permeability. Importantly, this lack of pericyte coverage can be compensated by co-administration of CXCL10. Our finding reveals a mechanism where TNF induces CXCL10 release from pericytes, being at the basis of increased permeability and thus vascular leakage.

2022-07-01 | GSE203505 | GEO

Physiological Vascular Permeability Requires Induction of Endothelial NR4A1 by Progesterone Receptor [ChIP-Seq]

Project description:Vascular permeability is frequently associated with inflammation and it is triggered by chemokines and by a cohort of secreted permeability factors, such as VEGF. In contrast, here we showed that the physiological vascular permeability that precedes implantation is directly controlled by progesterone receptor (PR) and it is independent of VEGF. Both global and endothelial-specific deletion of PR block physiological vascular permeability in the uterus while misexpression of PR in the endothelium of other organs results in ectopic vascular leakage. Integration of genome-wide transcriptional profile of endothelium and ChIP-sequencing revealed that PR induces a NR4A1 (Nur77/TR3) specific transcriptional program that broadly regulates vascular permeability in response to progesterone. This program triggers concurrent suppression of several junctional proteins and leads to an effective, timely and venule-specific regulation of vascular barrier function. Silencing NR4A1 blocks PR-mediated permeability responses indicating a direct link between PR and NR4A1. These results reveal a previously unknown function for progesterone receptor on endothelial cell biology with consequences to physiological vascular permeability and implications to the clinical use of progestins and anti-progestins on blood vessel integrity. Examination of PR binding sites in HUVEC cells using ChIP-seq (non-infected-negative control, PR infected followed by ligand treatment-PR+P or vehicle PR)

2014-01-01 | E-GEOD-43786 | biostudies-arrayexpress

Physiological Vascular Permeability Requires Induction of Endothelial NR4A1 by Progesterone Receptor [RNA-Seq]

Project description:Vascular permeability is frequently associated with inflammation and it is triggered by chemokines and by a cohort of secreted permeability factors, such as VEGF. In contrast, here we showed that the physiological vascular permeability that precedes implantation is directly controlled by progesterone receptor (PR) and it is independent of VEGF. Both global and endothelial-specific deletion of PR block physiological vascular permeability in the uterus while misexpression of PR in the endothelium of other organs results in ectopic vascular leakage. Integration of genome-wide transcriptional profile of endothelium and ChIP-sequencing revealed that PR induces a NR4A1 (Nur77/TR3) specific transcriptional program that broadly regulates vascular permeability in response to progesterone. This program triggers concurrent suppression of several junctional proteins and leads to an effective, timely and venule-specific regulation of vascular barrier function. Silencing NR4A1 blocks PR-mediated permeability responses indicating a direct link between PR and NR4A1. These results reveal a previously unknown function for progesterone receptor on endothelial cell biology with consequences to physiological vascular permeability and implications to the clinical use of progestins and anti-progestins on blood vessel integrity. Examination of PR target genes in human umbilical vein endothelial cells (HUVECs) using RNA-seq (PR infected only -PR only and PR infected followed by ligand treatment-PR+P)

2014-01-01 | E-GEOD-43788 | biostudies-arrayexpress

Gene expression changes due to PARP knockdown in human cells

Project description:To address the global impact of PARP-1 on the transcriptome, we knocked down PARP1 using siRNA from Dharmacon. Total RNA in three biological replicates from control (non-treated) and PARP-1 siRNA-treated cells were isolated. Sequencing of these RNAs on an Illumina NextSeq 500 yielded >56 million 75-bp RNA-seq reads. First we tested if PARP-1 KD was effective at the RNA-seq level. Reads aligning to the entire gene body of PARP-1 show a reduction in PARP-1 expression of about 1.5-fold (P-value < 0.0003), confirming that indeed PARP-1 was depleted after PARP-1 siRNA treatment. We next used these RNA-seq data sets (control and PARP-1 KD) to assess whether these treatments resulted in changes in gene expression and alternative splicing.

2018-02-14 | GSE91051 | GEO

Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_drug_treated]

Project description:Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells. These patients frequently develop malignant serous effusions (MSE). The value of MSE-based tumor cell characterization for guiding precision oncology is, however, currently unclear. Here, we present a comprehensive characterization of a pan-cancer cohort of 150 MSE samples at the cellular, molecular, and functional level. Our integrative analysis reveals dynamic cellular heterogeneity in MSE, and uncovers links between tumor driver mutations and ex vivo growth patterns. Strong concordance between genomic and transcriptional profiles of MSE and their corresponding solid tumors validates their use as a model system for solid tumor biology. We link baseline gene expression patterns to global ex vivo drug sensitivity, and demonstrate that drug-induced transcriptional changes in MSE are highly indicative of compound mode of action. Two case studies exemplify the utility of our approach in investigating acquired resistance to targeted therapy and identifying treatment options for relapsed solid tumors. In summary, our study provides a functional multi-omics view on a pan-cancer MSE cohort and underlines the utility of MSE-based precision oncology.

2024-08-26 | GSE240951 | GEO

Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_baseline]

2024-08-26 | GSE240952 | GEO